Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback